Table 3.

Pretreatment basic fibroblast growth factor (bFGF) levels in plasma

Cycle	Number of patients	Range (pg/ml)	Median (pg/ml)	Mean ± SD (pg/ml)
1	17	Undetectable—23.3	2.64	5.41 ± 6.46
2	16	1.6–10.4	3.16	4.30 ± 2.73
3	13	0.78–67.6	3.22	10.4 ± 18.7
4	9	Undetectable—25.5	3.11	7.19 ± 10.3
5	8	0.78–63.8	4.55	12.8 ± 21.1
6	5	2.99–18.5	9.13	10.1 ± 6.62
7	3	1.10–4.02	2.8	2.64 ± 1.47
8	3	2.5–35.5	4.02	14.0 ± 18.6
9	2	10.4–13.7	12.0	12.0 ± 2.31
10	1	4.72	NA	NA
11	1	22.9	NA	NA

Eighteen patients received a total of 79 cycles. Data shown are from 78 cycles, as the sample from one cycle was not available. Samples were obtained prior to each treatment cycle of suramin plus docetaxel on day 1, and prior to each treatment on days 1 and 8 of each cycle of suramin plus gemcitabine. bFGF level was measured using ELISA assay; the lower detection limit was 2.5 pg/ml

NA not applicable